Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TENAX THERAPEUTICS, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,274 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Purchase · Acquired 53,000 · Balance 55,274 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 30,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 80,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 100,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 4 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,200.00 · Expires 2031-06-10 | Direct | 4 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 4 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Biohaven Pharmaceutical Holding Co Ltd.
Report date December 31, 2021 · Filed February 11, 2022
Section 16 reporting ended · disclosed 2022-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-11-30 transaction · row 28
4 source rows · reconciled sequenceRow 1 · 2021-03-08 · Gift · Disposed 210,000 · Balance 610,647 Row 12 · 2021-05-18 · Gift · Disposed 113,912 · Balance 496,735 Row 26 · 2021-11-22 · Gift · Disposed 491,260 · Balance 5,475 Row 28 · 2021-11-30 · Gift · Disposed 5,475 · Balance 0 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 140,000 |
Reported balance
After 2021-03-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-03-08 · Gift · Acquired 140,000 · Balance 140,000 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 84 |
Reported balance
After 2021-03-18 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2021-03-18 · Gift · Disposed 139,916 · Balance 84 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 132,985 |
Reported balance
After 2021-03-24 transaction · row 11
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 11 · 2021-03-24 · Gift · Acquired 132,901 · Balance 132,985 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 246,897 |
Reported balance
After 2021-05-18 transaction · row 13
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 13 · 2021-05-18 · Gift · Acquired 113,912 · Balance 246,897 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 278,437 |
Reported balance
After 2021-05-18 transaction · row 14
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 14 · 2021-05-18 · Gift · Acquired 31,540 · Balance 278,437 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 108,437 |
Reported balance
After 2021-05-21 transaction · row 18
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 18 · 2021-05-21 · Other · Disposed 170,000 · Balance 108,437 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 129,237 |
Reported balance
After 2021-05-21 transaction · row 19
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 19 · 2021-05-21 · Gift · Acquired 20,800 · Balance 129,237 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 136,252 |
Reported balance
After 2021-10-14 transaction · row 23
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 23 · 2021-10-14 · Gift · Acquired 7,015 · Balance 136,252 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 627,512 |
Reported balance
After 2021-11-22 transaction · row 27
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 27 · 2021-11-22 · Gift · Acquired 491,260 · Balance 627,512 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan Revocable Trust | 632,987 |
Reported balance
After 2021-11-30 transaction · row 29
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 29 · 2021-11-30 · Gift · Acquired 5,475 · Balance 632,987 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 70,000 |
Reported balance
After 2021-03-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-03-08 · Gift · Acquired 70,000 · Balance 70,000 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 9,225 |
Reported balance
After 2021-03-16 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-03-16 · Gift · Disposed 60,775 · Balance 9,225 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 31,540 |
Reported balance
After 2021-03-22 transaction · row 9
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 9 · 2021-03-22 · Gift · Acquired 22,315 · Balance 31,540 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 52,340 |
Reported balance
After 2021-05-18 transaction · row 16
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 16 · 2021-05-18 · Gift · Acquired 20,800 · Balance 52,340 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 20,800 |
Reported balance
After 2021-05-18 transaction · row 17
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 17 · 2021-05-18 · Gift · Disposed 31,540 · Balance 20,800 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 0 |
Reported balance
After 2021-05-21 transaction · row 21
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 21 · 2021-05-21 · Gift · Disposed 20,800 · Balance 0 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan Revocable Trust | 7,342 |
Reported balance
After 2021-10-14 transaction · row 25
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 25 · 2021-10-14 · Gift · Acquired 7,342 · Balance 7,342 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 60,775 |
Reported balance
After 2021-03-16 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-03-16 · Gift · Acquired 60,775 · Balance 60,775 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 38,460 |
Reported balance
After 2021-03-22 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2021-03-22 · Gift · Disposed 22,315 · Balance 38,460 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 17,660 |
Reported balance
After 2021-05-18 transaction · row 15
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 15 · 2021-05-18 · Gift · Disposed 20,800 · Balance 17,660 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 187,660 |
Reported balance
After 2021-05-21 transaction · row 20
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 20 · 2021-05-21 · Other · Acquired 170,000 · Balance 187,660 |
| Common SharesSEC Table I · non-derivative | IndirectDorothy Doogan 2020 Trust | 180,318 |
Reported balance
After 2021-10-14 transaction · row 24
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 24 · 2021-10-14 · Gift · Disposed 7,342 · Balance 180,318 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan 2021 Trust | 139,916 |
Reported balance
After 2021-03-18 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2021-03-18 · Gift · Acquired 139,916 · Balance 139,916 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan 2021 Trust | 7,015 |
Reported balance
After 2021-03-24 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2021-03-24 · Gift · Disposed 132,901 · Balance 7,015 |
| Common SharesSEC Table I · non-derivative | IndirectDeclan Doogan 2021 Trust | 0 |
Reported balance
After 2021-10-14 transaction · row 22
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 22 · 2021-10-14 · Gift · Disposed 7,015 · Balance 0 |
| Common SharesSEC Table I · non-derivative | IndirectBy the Declan Doogan 2014 Trust | 676,002 |
Reported balance
Holding disclosure · report date 2021-12-31 · row 30
Holding and transaction disclosures are not merged.
1 source rowRow 30 · Balance 676,002 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2019 Filed Feb 26, 2019 17:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 20,334 | $45.25 | $920,113.50 |
DisclosureSEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 3 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,954 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.70 - $45.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 16,050 | $44.97 | $721,768.50 |
DisclosureSEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,288 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 - $45.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 17:44 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 5,575 | $44.11 | $245,913.25 |
DisclosureSEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,338 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.54 - $44.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 17:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,400 | $45.51 | $63,714.00 |
DisclosureSEC source: 0001209191-19-011732 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Declan Doogan 2014 Trust Disclosed balance after: 1,113,924 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.44 - $45.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 17:40 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 678 | $45.42 | $30,794.76 |
DisclosureSEC source: 0001209191-19-011732 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Declan Doogan 2014 Trust Disclosed balance after: 1,115,324 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $45.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 13, 2019 Filed Feb 14, 2019 16:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 6,158 | $44.24 | $272,429.92 |
DisclosureSEC source: 0001209191-19-010219 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Declan Doogan 2014 Trust Disclosed balance after: 1,116,002 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.23 - $44.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 16:42 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 33,842 | $44.32 | $1,499,877.44 |
DisclosureSEC source: 0001209191-19-010219 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,122,160 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.23 - $44.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 16:26 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 40,000 | $41.95 | $1,678,000.00 |
DisclosureSEC source: 0001209191-18-061265 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,156,002 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.91 - $42.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 16:19 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 300 | $36.00 | $10,800.00 |
DisclosureSEC source: 0001209191-18-036048 · doc4.xml · nonDerivative · entry 3 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,196,002 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 05, 2018 Filed Jun 6, 2018 16:19 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 49,463 | $35.41 | $1,751,484.83 |
DisclosureSEC source: 0001209191-18-036048 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,196,302 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 - $35.98, inclusive. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 16:19 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 39,453 | $35.05 | $1,382,827.65 |
DisclosureSEC source: 0001209191-18-036048 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,245,765 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 - $35.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| June 01, 2018 Filed Jun 1, 2018 17:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 83,898 | $35.04 | $2,939,785.92 |
DisclosureSEC source: 0001209191-18-034780 · doc4.xml · nonDerivative · entry 3 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,285,218 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 - $35.17, inclusive. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 17:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 26,044 | $35.01 | $911,800.44 |
DisclosureSEC source: 0001209191-18-034780 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,369,116 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 - $35.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 17:29 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 842 | $35.00 | $29,470.00 |
DisclosureSEC source: 0001209191-18-034780 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,395,160 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 01, 2018 Filed May 3, 2018 17:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $28.76 | $0.00 |
DisclosureSEC source: 0001209191-18-027734 · doc4.xml · derivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Shares · 18,000 shares Expires 2028-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 1, 2019 or (b) the date of the 2019 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| January 18, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 100 | $29.22 | $2,922.00 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 8 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,396,002 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 18, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 17,671 | $28.71 | $507,334.41 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 7 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,396,102 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.21 - $29.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (9) to this Form 4. Read SEC document |
| January 18, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 5,618 | $27.87 | $156,573.66 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 6 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,413,773 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 - $28.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4. Read SEC document |
| January 18, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 4,546 | $26.71 | $121,423.66 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 5 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,419,391 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 - $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 37,530 | $26.84 | $1,007,305.20 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 4 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,423,937 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.64 - $27.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 23,726 | $26.19 | $621,383.94 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 3 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,461,467 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.64 - $26.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,834 | $27.07 | $49,646.38 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,485,193 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.03 - $27.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 18:57 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 37,033 | $26.59 | $984,707.47 |
DisclosureSEC source: 0001209191-18-004394 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,487,027 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.03 - $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · balance_after: Includes 346,002 shares received by the Reporting Person from by Portage Biotech Inc. as a distribution in kind on a pro rata basis to its shareholders, effective January 15, 2017, which transaction was not required to be reported under SEC rules (the "Distribution"). Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 19,843 | $26.53 | $526,434.79 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 8 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,178,058 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.42 - $26.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 13,599 | $26.19 | $356,157.81 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 7 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,197,901 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.42 - $26.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 1,392 | $26.77 | $37,263.84 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 6 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,211,500 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.72 - $26.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 46,746 | $26.27 | $1,228,017.42 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 5 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,212,892 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.71 - $26.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 100 | $29.98 | $2,998.00 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 4 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,259,638 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 2,600 | $29.31 | $76,206.00 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 3 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,259,738 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.84 - $29.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 13,793 | $28.34 | $390,893.62 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 2 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,262,338 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.83 - $28.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 19:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | SaleCommon Shares | 23,869 | $27.13 | $647,565.97 |
DisclosureSEC source: 0001209191-18-003475 · doc4.xml · nonDerivative · entry 1 Doogan Declan · CIK 0001704234 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Declan Doogan 2014 Trust Disclosed balance after: 1,276,131 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.81 - $27.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.